New hope for brain cancer patients: drug combo targets aggressive tumors
NCT ID NCT06336291
First seen Apr 25, 2026 · Last updated Jun 18, 2026 · Updated 15 times
Summary
This study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in adequate health to receive treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia (UVA)
Charlottesville, Virginia, 22903, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.